Media stories about Pharmerica Corporation (NYSE:PMC) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pharmerica Corporation earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.0982470616715 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Dimensional Fund Advisors Lp Modifies Its Holdings in Pharmerica Corporation (PMC) Stock (overnewsmagazine.com)
- Head to Head Review: Pharmerica Corporation (NYSE:PMC) & Cardinal Health (CAH) (americanbankingnews.com)
- Pharmerica Corporation (NYSE:PMC) Receives Consensus Rating of “Hold” from Brokerages (overnewsmagazine.com)
- Pharmerica Corporation (NYSE:PMC) Lowered to “Overweight” at KeyCorp (americanbankingnews.com)
- Research Analysts Offer Predictions for Pharmerica Corporation’s Q4 2018 Earnings (PMC) (americanbankingnews.com)
A number of equities analysts have recently weighed in on PMC shares. ValuEngine downgraded shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 23rd. Credit Suisse Group downgraded shares of Pharmerica Corporation from an “outperform” rating to a “neutral” rating and upped their price target for the stock from $29.00 to $29.25 in a research note on Friday, August 4th. They noted that the move was a valuation call. BidaskClub downgraded shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, KeyCorp downgraded shares of Pharmerica Corporation to an “overweight” rating in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.83.
Pharmerica Corporation (NYSE:PMC) opened at 29.05 on Friday. Pharmerica Corporation has a 1-year low of $19.20 and a 1-year high of $29.10. The firm has a market capitalization of $904.07 million, a P/E ratio of 39.36 and a beta of 0.92. The stock has a 50 day moving average of $26.64 and a 200-day moving average of $24.94.
Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.47. Pharmerica Corporation had a net margin of 1.05% and a return on equity of 10.94%. The firm had revenue of $592 million for the quarter, compared to analyst estimates of $592.96 million. During the same period in the previous year, the business earned $0.47 EPS. The company’s revenue was up 13.9% compared to the same quarter last year. On average, equities research analysts anticipate that Pharmerica Corporation will post $1.92 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Pharmerica Corporation (NYSE:PMC) Receiving Somewhat Positive Press Coverage, Report Finds” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://transcriptdaily.com/2017/08/13/pharmerica-corporation-nysepmc-receiving-somewhat-positive-press-coverage-report-finds.html.
About Pharmerica Corporation
Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.